Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

64.51
+0.90001.41%
Post-market: 65.801.29+2.00%19:30 EDT
Volume:684.73K
Turnover:44.27M
Market Cap:2.48B
PE:-9.83
High:66.55
Open:64.56
Low:63.81
Close:63.61
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:1.09
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:3.84
PE(LYR):-10.73

Loading ...

Disc Medicine - Apollo Study Data Expected Q4 2026; FDA Decision Expected by Mid-2027

THOMSON REUTERS
·
Jun 09

Disc Medicine - FDA Agrees Phase 3 Apollo Study Can Support Crl Response and Potential Approval

THOMSON REUTERS
·
Jun 09

Disc Medicine Provides Update From FDA Type a Meeting for Bitopertin in Erythropoietic Protoporphyria

THOMSON REUTERS
·
Jun 09

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

GlobeNewswire
·
Jun 09

Assessing Disc Medicine (IRON) Valuation After New Trial Data And Expanded Access Program News

Simply Wall St.
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)

TIPRANKS
·
Jun 05

Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Celcuity (CELC)

TIPRANKS
·
Jun 03

Why Disc Medicine (IRON) Is Up 7.7% After Advancing Key Late-Stage Anemia Candidates

Simply Wall St.
·
Jun 03

Disc Medicine Presents Updated Positive Data From Rally-Mf Phase 2 Trial in Patients With Myelofibrosis (Mf) and Anemia at the 2026 American Society of Clinical Oncology (Asco) Annual Meeting

THOMSON REUTERS
·
Jun 02

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Jun 02

Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - CHANGES TO THE BOARD OF DIRECTORS AND COMMITTEE LEADERSHIP

Dow Jones
·
Jun 02

Disc Medicine - Bitopertin Phase 3 Apollo Trial Topline Data Expected in Q4 2026

THOMSON REUTERS
·
Jun 01

Disc Medicine - Launches Expanded Access Program for Bitopertin for Epp and Xlp Patients in U.S.

THOMSON REUTERS
·
Jun 01

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

GlobeNewswire
·
Jun 01

Press Release: CHAMPION IRON REPORTS ITS FY2026 FOURTH QUARTER RESULTS

Dow Jones
·
May 28

H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
May 27

Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?

Simply Wall St.
·
May 17

Disc Medicine Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 15

Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating

MT Newswires Live
·
May 14